Boston Scientific Corp. vs. Avita Medical, Inc. Common Stock
Boston Scientific Corp. (BSX) comes out ahead, leading on 5 of 8 compared factors.
Size & Scale
| BSX | RCEL | |
|---|---|---|
| Market Cap | $63.36 billion | $347.00 million |
| Revenue (TTM) | $21.00 billion | $75.63 million |
| Net Income (TTM) | $3.67 billion | $-43,082,000 |
BSX leads on 3 of 3 size & scale factors.
Valuation
| BSX | RCEL | |
|---|---|---|
| P/E Ratio | 18.19 | — |
| Price / Book | 2.52 | -12.46 |
| Price / Sales | 3.02 | 4.59 |
BSX and RCEL split the valuation factors evenly.
Profitability
| BSX | RCEL | |
|---|---|---|
| Net Margin | 17.47% | -56.96% |
| Return on Equity | 14.57% | 154.76% |
BSX and RCEL split the profitability factors evenly.
Risk & Sentiment
| BSX | RCEL | |
|---|---|---|
| Short Interest | 0.72% | 0.34% |
RCEL leads on 1 of 1 risk & sentiment factors.
Dig deeper: BSX overview, BSX financials, RCEL overview, RCEL financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.